⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18519861 | 0.74 | — | — | |
| SCHEMBL23894356 | 0.73 | — | — | |
| SCHEMBL6831182 | 0.72 | — | — | |
| SCHEMBL20806094 | 0.72 | — | — | |
| SCHEMBL10041948 | 0.72 | — | — | |
| SCHEMBL6831180 | 0.72 | — | — | |
| SCHEMBL22138880 | 0.72 | — | — | |
| SCHEMBL12657618 | 0.72 | TDP1 (0.38) | — | |
| SCHEMBL24548438 | 0.72 | TDP1 (0.38) | — | |
| SCHEMBL12758184 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205164-A1 | PROCESSES FOR THE PREPARATION OF FINERENONE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023138336-A1 | METHOD FOR PREPARING FINERENONE AND INTERMEDIATE THEREOF | 奥锐特药业股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| EP-3174875-B1 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE AND THE PURIFICATION THEREOF FOR USE AS AN ACTIVE PHARMACEUTICAL INGREDIENT | Bayer Pharma AG (DE) | 2020-08-19 | — | — | EP | disclosed |
| EP-3660015-A1 | METHOD FOR THE PREPARATION OF (4S)- 4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL- 1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOX-AMIDE AND ITS PURIFICATION FOR USE AS PHARMACEUTICAL SUBSTANCE | Bayer Pharma Aktiengesellschaft (DE) | 2020-06-03 | — | — | EP | disclosed |